Nexavar has not met its Phase III trial primary endpoint of improving the overall survival of patients with advanced non-small cell lung cancer in the first-line setting.

The drug was evaluated in combination with chemotherapeutic agents gemcitabine and cisplatin during the trial, with results compared to a placebo control group.

However, a positive secondary endpoint of progression-free survival was observed.

The safety and tolerability of the treatment triplet was as expected and the drug did not show any new or unexpected toxicities.

Nexavar, developed and marketed by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, is currently being used to treat liver cancer and kidney cancer.

Bayer HealthCare’s vice-president of global clinical development for oncology, Dr Dimitris Voliotis, said the firm would continue to evaluate Nexavar in combination with targeted agents, based on positive findings from other studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData